
Senate Committee Maintains Federal Barriers on DC Marijuana Sales and Drug Testing Rules
A Senate committee has advanced spending bills that keep blocking D.C. from legalizing cannabis sales and require continued federal drug testing for safety-sensitive jobs, even if marijuana is rescheduled
Key Points
- 1Senate Appropriations Committee released FY2027 spending bills maintaining the ban on D.C. legalizing recreational cannabis sales
- 2Federal agencies are directed to continue drug testing safety-sensitive workers for cannabis, regardless of possible rescheduling
- 3The committee acknowledges research barriers posed by Schedule I status and encourages expanded research into psychedelics and neuroplastogens
- 4A provision requires the State Department to report on Chinese-linked illegal cannabis cultivation in the U.S
- 5Federal funding for promoting legalization of Schedule I drugs remains prohibited in the proposed bills
A newly released set of U.S. Senate appropriations bills would maintain longstanding federal restrictions on Washington, D.C.'s ability to legalize recreational cannabis sales while directing federal agencies to continue drug testing safety-sensitive workers for marijuana—even if federal rescheduling moves forward. According to Marijuana Moment, the Senate Appropriations Committee's Fiscal Year 2027 spending proposals include provisions that specifically block D.C. from enacting local adult-use cannabis regulations and instruct the Department of Transportation to uphold current drug testing protocols for workers such as pilots and truck drivers
The attached report to the Transportation and Housing and Urban Development (THUD) bill emphasizes the committee's concerns about workforce safety. "Drug Testing.—The Committee directs the Department of Transportation to maintain current drug testing requirements for cannabis to ensure the continued safety of the Nation’s transportation systems," the report states. It further warns that relaxing these requirements could "compromise workforce safety and regulatory consistency," citing the lack of a scientifically validated impairment threshold for cannabis
In addition to the D.C. sales prohibition, the Financial Services and General Government (FSGG) bill renews a federal funding rider that prevents any use of funds to legalize or reduce penalties for Schedule I substances, including cannabis, in the District. The FSGG report also cautions D.C. officials about the proximity of medical marijuana dispensaries to schools, noting that federal law still imposes enhanced penalties for drug distribution near educational institutions and other child-focused properties
Other appropriations bills released by the committee address the broader landscape of drug research and policy. The Labor and Health and Human Services (LaborH) bill reiterates a ban on using federal funds to promote legalization of Schedule I drugs but also acknowledges the challenges that Schedule I status creates for scientific research. "The Committee is concerned that restrictions associated with Schedule I of the Controlled Substances Act effectively limit the amount and type of research that can be conducted on certain Schedule I drugs, especially opioids, psychedelics, marijuana or its component chemicals, and new synthetic drugs and analogs," the report notes. The committee urges agencies to address these barriers and encourages expanded research into the therapeutic potential of psychedelics and neuroplastogens for substance use and mental health disorders
Further, the committee calls on the Centers for Medicare & Medicaid Services (CMS) to track and report hospital costs linked to marijuana use, and recommends the National Institutes of Health (NIH) and Substance Abuse and Mental Health Services Administration (SAMHSA) prioritize research and workforce training for emerging treatments, including psychedelic therapies and neuromodulation technologies. Additionally, a separate provision instructs the State Department to report to Congress on Chinese-linked illegal cannabis cultivation operations within the U.S., highlighting ongoing federal concern about illicit market dynamics
OG Lab notes that these Senate appropriations bills reflect a cautious federal approach, balancing incremental research support and workforce safety with continued resistance to broader legalization measures. As the debate over cannabis policy evolves, stakeholders should watch for potential changes in federal research access, local regulatory autonomy in D.C., and the interplay between rescheduling efforts and workplace drug testing rules


